TY - JOUR
T1 - Microglia-mediated regulation of neuropathic pain
T2 - Molecular and cellular mechanisms
AU - Tsuda, Makoto
N1 - Funding Information:
Acknowledgments This work was supported by JSPS KAKENHI Grant Number 19H05658, by the Core Research for Evolutional Science and Technology (CREST) program from Japan Agency for Medical Research and Development (AMED) under Grant Number 19gm0910006, and Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number 19am0101091.
Funding Information:
Makoto Tsuda received his Ph.D. from Hoshi University (Tokyo, Japan) in 1998. He then worked as a postdoctoral fellow in the laboratories of Dr. Kazuhide Inoue at National Institute of Health Science (NIHS; Tokyo, Japan; 1998–2002) and of Dr. Michael Salter at Hospital for Sick Children (Toronto, Canada; 2002–2004). He then returned to the laboratory of Dr. Inoue at NIHS as Research Associate (2004–2005). He was appointed as Assistant Professor at Graduate School of Pharmaceutical Sciences, Kyushu University (Fukuoka, Japan) in 2005, as Associate Professor in 2006 and as Professor (2014). He received The Award for Young Investigator of JPS (2007), The Award of Young Scientist from MEXT of Japan (2007), The Award for Distinguished Young Investigator of JSN (2007), and The Pharmaceutical Society of Japan Award for Divisional Scientific Promotion (2019). Work in his laboratory is primarily directed at elucidating glia–neuron interactions in the spinal cord and brain, to understanding the cellular and molecular mechanisms of pain and itch, and to devising strategies for new types of pain and itch relieving medications.
PY - 2019
Y1 - 2019
N2 - Pain is a defense system that responds rapidly to harmful internal and external stimuli through the somatosensory neuronal pathway. However, damage to the nervous system through cancer, diabetes, infection, autoimmune disease, chemotherapy or trauma often leads to neuropathic pain, a debilitating chronic pain condition. Neuropathic pain is not simply a temporal continuum of acute nociceptive signals from the periphery, but rather due to pathologically altered functions in the nervous system, which shift the net neuronal excitatory balance toward excitation. Although alterations were long thought to be a result of changes in neurons, but an increasing body of evidence over the past decades indicates the necessity and sufficiency of microglia, the tissue-resident macrophages of the spinal cord and brain, for nerve injury-induced malfunction of the nervous system. In this review article, I describe our current understanding of the molecular and cellular mechanisms underlying the role of microglia in the pathogenesis of neuropathic pain and discuss the therapeutic potential of microglia from recent advances in the development of new drugs targeting microglia.
AB - Pain is a defense system that responds rapidly to harmful internal and external stimuli through the somatosensory neuronal pathway. However, damage to the nervous system through cancer, diabetes, infection, autoimmune disease, chemotherapy or trauma often leads to neuropathic pain, a debilitating chronic pain condition. Neuropathic pain is not simply a temporal continuum of acute nociceptive signals from the periphery, but rather due to pathologically altered functions in the nervous system, which shift the net neuronal excitatory balance toward excitation. Although alterations were long thought to be a result of changes in neurons, but an increasing body of evidence over the past decades indicates the necessity and sufficiency of microglia, the tissue-resident macrophages of the spinal cord and brain, for nerve injury-induced malfunction of the nervous system. In this review article, I describe our current understanding of the molecular and cellular mechanisms underlying the role of microglia in the pathogenesis of neuropathic pain and discuss the therapeutic potential of microglia from recent advances in the development of new drugs targeting microglia.
UR - http://www.scopus.com/inward/record.url?scp=85075783273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075783273&partnerID=8YFLogxK
U2 - 10.1248/bpb.b19-00715
DO - 10.1248/bpb.b19-00715
M3 - Review article
C2 - 31787711
AN - SCOPUS:85075783273
VL - 42
SP - 1959
EP - 1968
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
SN - 0918-6158
IS - 12
ER -